Global Prion Disease Treatment Market, By Types (Creutzfeldt-Jakob Disease (CJD), Variant Creutzfeldt-Jakob Disease (CJD), Variably Protease-Sensitive Prionopathy, Gerstmann-Sträussler-Scheinker Disease and Others), Drug (Antidepressant, Antipsychotic Agents and Others), Route of Administration(Oral and Injectable), End-Users (Hospitals, Homecare, Specialty Clinics, Others) - Industry Trends and Forecast to 2030.
Prion Disease Treatment Market Analysis and Size
Major factors that are expected to boost the growth of the prion disease treatment market in the forecast period are the genetic history of prion disease. Furthermore, the initiatives and support taken by the government for the advancement of orphan drugs are further anticipated to propel the growth of the prion disease treatment market. On the other hand, the specific treatment for the disease is less accessible because of minimal incidence of prion disease is further projected to impede the growth of the prion disease treatment market in the timeline period.
In addition, the rise in the demand for certain kinds of treatment for prion disease will further provide potential opportunities for the growth of the prion disease treatment market in the coming years. However, the dearth of awareness and a limited amount of knowledge regarding the prion disease in a few advancing countries might further create challenges for the growth of the prion disease treatment market shortly.
Data Bridge Market Research analyses that the prion disease treatment market which was USD 4,669.10 million in 2022, would rocket up to USD 6,846.00 million by 2030, and is expected to undergo a CAGR of 4.90% during the forecast period. This indicates the market value. "Medication" dominates the treatment segment of the prion disease treatment market due to increasing awareness about prion disease treatment. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Prion Disease Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Types (Creutzfeldt-Jakob Disease (CJD), Variant Creutzfeldt-Jakob Disease (CJD), Variably Protease-Sensitive Prionopathy, Gerstmann-Sträussler-Scheinker Disease, Others), Drug (Antidepressant, Antipsychotic Agents and Others), Route of Administration(Oral and Injectable), End-Users (Hospitals, Homecare, Specialty Clinics, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa
|
|
Market Players Covered
|
Rocket Pharmaceuticals, Ltd. (U.S.), Sanofi (France), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), AstraZeneca (U.K.), and Array BioPharma (U.S.), Teva Pharmaceutical Industries Ltd., (Israel), Sun Pharmaceutical Industries Ltd., (India), Cipla Inc. (India) among others.
|
|
Market Opportunities
|
|
Market Definition
Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are a group of rare, progressive, and invariably fatal neurodegenerative disorders that affect humans and animals. These diseases are characterized by the accumulation of abnormal forms of a cellular protein called prion protein (PrP) in the brain, leading to the destruction of brain tissue.
The market for prion disease treatment includes the production, distribution, and sales of the medication worldwide. It involves pharmaceutical companies that manufacture prion disease treatment, healthcare facilities where it is administered, and various stakeholders such as physicians, patients, and regulatory authorities involved in its prescription, usage, and approval.
Prion Disease Treatment Market Dynamics
Drivers
- Increasing Prevalence of Prion Disease
There has been a growing recognition and understanding of prion and other brain-related disorders. The prevalence of prion diseases, such as Creutzfeldt-Jakob disease (CJD), variant CJD, and Gerstmann-Sträussler-Scheinker syndrome (GSS), has been increasing worldwide. This rising prevalence creates a need for effective treatments, driving the demand for prion disease treatments.
- Growing Research and Development Activities
The scientific community and pharmaceutical companies are actively engaged in research and development efforts to better understand the mechanisms underlying prion diseases and to develop novel treatment options. This focus on R&D is driving innovation and contributing to the expansion of the prion disease treatment market.
- Government Initiatives and Funding
Governments and research organizations are recognizing the significance of prion diseases and their impact on public health. Consequently, they are providing funding and support for research projects, clinical trials, and the development of prion disease treatments. These initiatives play a crucial role in advancing treatment options and driving market growth.
Opportunity
- Advancements in Diagnostic Techniques
Improvements in diagnostic techniques, such as biomarker identification and the development of sensitive and specific diagnostic tests, have contributed to the early and accurate detection of prion diseases. Early diagnosis allows for timely intervention and treatment, leading to increased demand for prion disease treatments.
Restraints/Challenges
- Limited awareness and understanding
Despite the increasing prevalence of Prion disease, there remains a lack of awareness and understanding among healthcare professionals, which can lead to delayed or misdiagnosis. This limited awareness can hinder timely access to appropriate treatments and delay the development of new therapeutic approaches.
This prion disease treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Prion disease treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In September 2022, Annovis Bio, a clinical-stage drug platform company addressing neurodegenerative diseases, announced the publication of three granted US patents – US11400075 (link), US11376238 (link), and US11382893 (link). The patents cover methods of treating amyloid lateral sclerosis (ALS), Huntington's disease, and prion diseases by administering buntanetap.
Global Prion Disease Treatment Market Scope
The prion disease treatment market is segmented on the basis of type, drug, route of administration, and end-users. The growth amongst these segments will help you meagre growth segments in the industries and provide the users with a valuable market overview and insights to help them make strategic decisions for identifying core market applications.
Type
- Creutzfeldt-Jakob Disease (CJD)
- Variant Creutzfeldt-Jakob Disease (CJD)
- Variably Protease-Sensitive Prionopathy
- Gerstmann-Sträussler-Scheinker Disease
- Others
Drug
- Antidepressant
- Antipsychotic Agents
- Others
Route of Administration
- Oral
- Injectable
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Prion disease treatment Market Regional Analysis/Insights
The prion disease treatment market is analysed and market size insights and trends are provided by country, type, drug, route of administration, and end-users as referenced above.
The countries covered in the prion disease treatment market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, rest of Middle East & Africa.
North America is dominating the global prion disease treatment market due to the increasing prevalence of the prion disease in that region.
Asia-Pacific is the fastest-growing region due to the increased geriatric population in the region.
The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The prion disease treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for prion disease treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the prion disease treatment market. The data is available for historic period 2015-2020.
Competitive Landscape and Prion Disease Treatment Market Share Analysis
The Prion disease treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the prion disease treatment market are:
- Rocket Pharmaceuticals, Ltd. (U.S.)
- Sanofi (France)
- GlaxoSmithKline plc (U.K.)
- Pfizer Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- AstraZeneca (U.K.)
- Array BioPharma (U.S.)
- Teva Pharmaceutical Industries Ltd., (Israel)
- Sun Pharmaceutical Industries Ltd., (India)
- Cipla Inc. (India)
SKU-